Viking Therapeutics, Inc. (VKTX) Advances Obesity Drug Development and Expands Metabolic Disease Pipeline [Yahoo! Finance]
Viking Therapeutics, Inc. (VKTX)
Last viking therapeutics, inc. earnings: 4/30 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.vikingtherapeutics.com
Company Research
Source: Yahoo! Finance
Data published in the peer-reviewed journal Obesity show that the drug achieved a weight loss of 14.7% from baseline after 13 weeks of treatment, with no plateau observed. The clinical trial also met both primary and secondary endpoints. Following the positive Phase 2 trials, Viking is evaluating VK2735 in the Phase 3 VANQUISH-1 trial. It has already enrolled about 4,650 patients. “The study data served to highlight the promise that VK2735 holds as a potentially best-in-class dual GLP-1/GIP agonist and were central to our designing of the ongoing VANQUISH Phase 3 program,” said Brian Lian, CEO of Viking Therapeutics. The positive clinical trials come as interest in weight loss drug deals remains strong in the market. According to Viking Therapeutics CEO Brian Lian, drug makers are increasingly seeking ways to tap into the potential $150 billion market. Viking Therapeutics, Inc. (NASDAQ:VKTX) is a clinical-stage biopharma company developing drugs for metabolic and endocrine dise
Show less
Read more
Impact Snapshot
Event Time:
VKTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VKTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VKTX alerts
High impacting Viking Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
VKTX
News
- 2 Biotech Stocks Set to Rebound in 2026 [Yahoo! Finance]Yahoo! Finance
- Why Viking Therapeutics (VKTX) Is Down 6.5% After Publishing VK2735 Phase 2 Obesity Trial Results And What's Next [Yahoo! Finance]Yahoo! Finance
- The Best Stocks to Invest $40 in to Start the New Year Off Right [Yahoo! Finance]Yahoo! Finance
- Assessing Viking Therapeutics (VKTX) Valuation As Shares Rebound Over The Past Week [Yahoo! Finance]Yahoo! Finance
- Viking Therapeutics (NASDAQ:VKTX) had its "sell (d-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
VKTX
Earnings
- 10/22/25 - Miss
VKTX
Analyst Actions
- 11/12/25 - Canaccord Genuity
VKTX
Sec Filings
- 1/26/26 - Form 4
- 1/26/26 - Form 3
- 1/5/26 - Form 4
- VKTX's page on the SEC website